| Symbol | ALMS |
|---|---|
| Name | ALUMIS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 280 EAST,GRAND AVENUE, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | 650-231-6625 |
| Fax | — |
| — | |
| Website | https://www.alumis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Alumis mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively. Additional info from NASDAQ: |
New Form SCHEDULE 13G - ALUMIS INC. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001172661-26-001395 <b>Size:</b> 11 KB
Read moreForesite Labs, LLC 🟡 adjusted position in 496.0K shares of ALUMIS INC. (ALMS) Transaction Date: Apr 01, 2026 | Filing ID: 039611
Read moreDirector Tananbaum James B. 🟡 adjusted position in 496.0K shares of ALUMIS INC. (ALMS) Transaction Date: Apr 01, 2026 | Filing ID: 039609
Read moreNew Form SCHEDULE 13D/A - ALUMIS INC. <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0001104659-26-039608 <b>Size:</b> 54 KB
Read more(90% Positive) ALUMIS INC. (ALMS) Provides Update on Symptoms for Two Phase 3 Trials
Read moreAlumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Read moreAlumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Read moreNew Form S-3ASR - ALUMIS INC. <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 0001104659-26-032158 <b>Size:</b> 1 MB
Read moreAlumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05739435 | Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK… | Phase2 | Plaque Psoriasis | Active_Not_Recruiting | 2023-01-17 | 2026-12-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | DRUG | Phase PHASE2 | SLE | ACTIVE_NOT_RECRUITING | NCT05966480 |
| Envudeucitinib | DRUG | Phase PHASE2 | SLE | ACTIVE_NOT_RECRUITING | NCT05966480 |
| envudeucitinib | DRUG | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT05739435 |